List view / Grid view
The algorithm can accurately diagnose cases of lung adenocarcinoma, determining structural features that are statistically most significant for assessing disease severity and likelihood of tumour recurrence.
Traditional wet lab scientists working on target discovery, drug identification and drug optimisation have an opportunity to catch up with their AI-enabled peers – but why should they, and how? In this article – the second of a three-part series – Dr Raminderpal Singh touches on methods that are being…
Traditional wet lab scientists working on target discovery, drug identification and drug optimisation have an opportunity to catch-up with their AI-enabled peers – but why should they, and how? In this article – the first of a three-part series – Dr Raminderpal Singh seeks to demystify the topic by outlining…
Dr Richard Cote and Dr Ramaswamy Govindan of the Washington University School of Medicine elucidate how AI, particularly deep learning networks, could identify histopathologic features in non-small cell lung cancer, and impact the treatment approach for early-stage patients.
Researchers have developed an algorithm which could improve diagnostics of ovarian high-grade serous carcinoma.
We had the privilege of speaking to Dr Víctor Sebastián Pérez, Associate Director of Computational Drug Design, following his presentation at ELRIG UK 2023. He shares his insights into how Exscientia is using AI to design drug candidates for cancer treatment.
Researchers have developed a computational analysis tool which will improve patient stratification and enable personalised medicine.
The computer model enables a better understanding of how drugs affect fibroblasts and finds a promising candidate to prevent heart scarring.
A deep learning model developed using circulating cell-free DNA outperformed traditional screening methods for gestational diabetes mellitus.
A new learning-based framework enables patients and caregivers to predict the timing of any of the five clinical groups of AD development.
The guide provides examples of how Transcreener allowed rapid assay development to enable screening for kinases in innate immune pathways.
The ML algorithm explores how genetic mutations collectively influence a tumour’s reaction to drugs impeding DNA replication.
New software can make protein molecules that bind with high affinity and specificity to many biomarkers, including human hormones.
A new deep-learning method could enhance therapeutic devices for people with neurological or mental health conditions.
An AI system could be used to observe how physical constraints shape brains and impact people with cognitive difficulties.
